Aurobindo Arm CuraTeQ Gets Health Canada NOC for Pegfilgrastim Biosimilar Dyrupe We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
New Delhi: Aurobindo Pharma Ltd on Friday said its arm CuraTeQ Biologics Pvt Ltd has received a notice of compliance from Health Canada for its biosimilar Dyrupeg, indicated to cancer patients with low levels of neutrophils, a type of white blood cell. CuraTeQ Biologics has obtained Notice of Compliance (NOC) from Biologics and Radiopharmaceutical Drugs…
Aurobindo Pharma Extends Timeline to Acquire 26% in Swarnaakshu Solar We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma Arm Seals Rs 3,250 Cr Deal to Acquire Khandelwal Labs’ Non-Oncology Brands We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma arm terminates Ustekinumab biosimilar pact with BioFactura We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
New Delhi, Aurobindo Pharma on Tuesday said that it will pick up an additional 20 per cent stake in its China-based joint venture for USD 5.12 million. Helix Healthcare BV, a wholly-owned subsidiary of the company, has entered into a binding agreement with Shandong Luoxin Pharmaceutical Group Stock Co, the joint venture partner in Luoxin…
Aurobindo Pharma arm to acquire 20% additional ownership in Luoxin Aurovitas for Rs 45 crore We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma Gets HC Relief in Compensation Cess Refund Dispute, GST Orders Quashed We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma on Thursday said the US health regulator has issued a Form 483 with five observations after inspecting Andhra Pradesh-based Unit-IV of its subsidiary APL Healthcare. The US Food and Drug Administration (USFDA) inspected the unit from December 8 to December 17, 2025, the Hyderabad-based drug firm said in a regulatory filing. “At the…
Aurobindo Pharma arm Unit IV gets 5 USFDA observations We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link